Shortage Reporting Should Be Over-Inclusive, FDA Tells Drugmakers
Draft guidance urges manufacturers to err on the side of over-reporting when it comes to vital drugs that may be going into shortage.
You may also be interested in...
FDA press conference on alleviating shortages shows how the agency works with industry to advance legislation that firms may not be particularly fond of themselves. But the agency still seems to face an uphill legislative battle.
Interim final rule redefines the terms “sole manufacturer” and “discontinuance.”
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.